Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Happich

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 5, 2018
Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementiaMark Belger, Josep Maria Haro, Catherine Reed, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 8, 2015
Determinants of societal costs in Alzheimer's disease: GERAS study baseline resultsRichard Dodel, Mark Belger, Catherine Reed, et al.
Journal of Comparative Effectiveness Research|September 1, 2017
Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetRealAmr Makady, Heather Stegenga, Antonio Ciaglia, et al.
The West Indian Medical Journal|February 23, 2016
Newborn Screening for Sickle Cell Disease: Jamaican ExperienceK Mason, F Gibson, R Gardner, et al.
Anticancer Research|March 16, 2004
Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC)K Link, K Happich, I Schirner, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 12, 2021
Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety netOlaf Sommerburg, Mirjam Stahl, Susanne Hämmerling, et al.
Annals of Intensive Care|November 9, 2023
Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective studyAntonia Greimel, Katharina Habler, Caroline Gräfe, et al.
Journal of Alzheimer'S Disease : JAD|May 1, 2013
The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findingsAnders Wimo, Catherine C Reed, Richard Dodel, et al.
BMC Medical Research Methodology|July 20, 2016
How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational studyMark Belger, Josep Maria Haro, Catherine Reed, et al.
Annals of Hematology|December 15, 2015
Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screeningJoachim B Kunz, Saida Awad, Margit Happich, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|September 5, 2018
Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementiaMark Belger, Josep Maria Haro, Catherine Reed, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 8, 2015
Determinants of societal costs in Alzheimer's disease: GERAS study baseline resultsRichard Dodel, Mark Belger, Catherine Reed, et al.
Journal of Comparative Effectiveness Research|September 1, 2017
Practical implications of using real-world evidence (RWE) in comparative effectiveness research: learnings from IMI-GetRealAmr Makady, Heather Stegenga, Antonio Ciaglia, et al.
The West Indian Medical Journal|February 23, 2016
Newborn Screening for Sickle Cell Disease: Jamaican ExperienceK Mason, F Gibson, R Gardner, et al.
Anticancer Research|March 16, 2004
Palliative second-line treatment with weekly high-dose 5-fluorouracil as 24-hour infusion and folinic acid (AIO) plus oxaliplatin after pre-treatment with the AIO-regimen in colorectal cancer (CRC)K Link, K Happich, I Schirner, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|November 12, 2021
Final results of the southwest German pilot study on cystic fibrosis newborn screening - Evaluation of an IRT/PAP protocol with IRT-dependent safety netOlaf Sommerburg, Mirjam Stahl, Susanne Hämmerling, et al.
Annals of Intensive Care|November 9, 2023
Extracorporeal adsorption of protective and toxic bile acids and bilirubin in patients with cholestatic liver dysfunction: a prospective studyAntonia Greimel, Katharina Habler, Caroline Gräfe, et al.
Journal of Alzheimer'S Disease : JAD|May 1, 2013
The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findingsAnders Wimo, Catherine C Reed, Richard Dodel, et al.
BMC Medical Research Methodology|July 20, 2016
How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational studyMark Belger, Josep Maria Haro, Catherine Reed, et al.
Annals of Hematology|December 15, 2015
Significant prevalence of sickle cell disease in Southwest Germany: results from a birth cohort study indicate the necessity for newborn screeningJoachim B Kunz, Saida Awad, Margit Happich, et al.
Pageof 10